Program Topics

Thank you to everyone who participated in the Summit topic selection survey. We received 66 responses, providing valuable feedback to help shape the direction of the PET Drug Manufacturing Summit. Following review of the survey results, the Program Committee met and identified six key discussion areas, which were addressed at the first Summit on November 11–12, 2026.

1

Wednesday, November 11 · 8:45–9:45 AM

FDA's Environmental Monitoring (EM) Enforcement

Discussion moderators: Marianna Dakanali (University of Michigan) and Richard Jahn (GE HealthCare)

Using prior Coalition Member EM survey data, combined with the results of real-time (in-the-meeting) Google QR code survey responses and live discussion, this session raised awareness of the approaches PET drug manufacturers were using for environmental monitoring, and provided direction for potential future Coalition position development and advocacy on this topic.

2

Wednesday, November 11 · 10:30–11:30 AM

Incoming Materials Testing

Discussion moderators: Robin Cumming (University of California, San Francisco) and Chris Parr (Pharmalogic)

The FDA has asserted that more complex precursors — such as those with multiple chiral centers — present an issue where existing HPLC methods for radiochemical identity and purity of finished drug products cannot resolve the stereoisomers, potentially requiring new finished-product or precursor identity testing. This session discussed developing a path forward for Coalition advocacy given that drug developers and their CDMOs may need to comply with the Agency's direction while academic producers/RDRCs may not face the same scrutiny, what compliance with the Agency's expectations would look like in practice, and potential alternative compliance pathways for the community.

3

Wednesday, November 11 · 12:45–1:45 PM

Addressing FDA Inconsistency and the Training Level of FDA Reviewers and Inspectors

Discussion moderators: David Dick (University of Iowa) and Eric Webster (Telix Pharmaceuticals)

This session gathered attendee input on (1) instances where FDA inspectors have stated they were not trained on relevant requirements, (2) instances of inconsistency across FDA audits, including cases where auditors applied different interpretations from one audit to another, and (3) what the Coalition can do to help close these gaps, including potential training options such as courses already available through SNMMI or offering to hold training sessions with FDA, potentially even at a member's facility.

4

Wednesday, November 11 · 2:00–3:30 PM

Communicating Risk Assessment and Justification with the FDA

Discussion moderators: Richard Jahn (GE HealthCare) and Cathy Cutler (Brookhaven National Labs)

This session examined how to anticipate FDA expectations by adopting a higher-level, systems-based perspective rather than focusing only on individual product issues. Attendees explored and proposed recommendations regarding the potential benefits, risks, and strategic considerations of aligning internal processes, risk assessments, and regulatory justifications with the broader FDA framework that guides both application review and inspection activities.

5

Thursday, November 12 · 8:45–9:45 AM

External Relationships: Effective Cultivation & Communication

Discussion moderators: Adam Rosenberg (Vanderbilt University) and Steve Zigler (PETNET)

This session explored and refined the Coalition's goals and desired outcomes for external relationships with the FDA, USP, and other regulatory bodies. Discussion covered the value of workshops, conference presentations, peer-reviewed publications and editorials, and potential technical reports (similar to those from the Parenteral Drug Association); the role of policy-level discussions with the FDA; and how to engage USP on the development and maintenance of public standards for PET drugs.

6

Thursday, November 12 · 10:15–11:15 AM

Theragnostics / Therapeutics

Discussion moderators: Cathy Cutler (Brookhaven National Labs) and Keith Bowen (Eli Lilly & Co)

This session examined whether the PET Drug Manufacturing Coalition should formally expand its role to include theranostic agents. It discussed the potential benefits of addressing shared manufacturing, quality, and regulatory needs, as well as the risks of overextension, overlap with existing organizations, and shifting regulatory expectations — with the goal of determining whether theranostics represent a natural and necessary evolution of the Coalition's mission.

These sessions were designed as collaborative, solutions-oriented discussions focused on identifying practical paths forward for the PET drug manufacturing community.